Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis
NCT07709910Phase 3Not yet recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and knee osteoarthritis (OA) comparing Ribupatide Injection with Placebo (2 arms). Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index pain score at 68 weeks and Percentage change from baseline in body weight at 68 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ribupatide
03
Conditions
obesityknee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07709910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07709910.